1990
DOI: 10.1016/0002-9149(90)91038-8
|View full text |Cite
|
Sign up to set email alerts
|

Effects of transdermal scopolamine on heart rate variability in normal subjects

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

1
18
0
3

Year Published

1992
1992
2016
2016

Publication Types

Select...
6
2
1

Relationship

0
9

Authors

Journals

citations
Cited by 81 publications
(22 citation statements)
references
References 24 publications
1
18
0
3
Order By: Relevance
“…They also showed that change from the supine to the 40°upright position did not lead to an increase in LF power. Finally, Vybiral et al demonstrated that administration of the vagomimetic transdermal scopolamine led to a significant increase in LF power in supine subjects (24). These data suggest a substantial degree of similarity in the autonomic profile of the seated and supine positions and that, in both, it appears that LF power principally reflects cardiac parasympathetic modulation.…”
Section: Discussionmentioning
confidence: 97%
“…They also showed that change from the supine to the 40°upright position did not lead to an increase in LF power. Finally, Vybiral et al demonstrated that administration of the vagomimetic transdermal scopolamine led to a significant increase in LF power in supine subjects (24). These data suggest a substantial degree of similarity in the autonomic profile of the seated and supine positions and that, in both, it appears that LF power principally reflects cardiac parasympathetic modulation.…”
Section: Discussionmentioning
confidence: 97%
“…Furthermore, procedures that increase HRV such as β-adrenergic receptor blockade, exercise conditioning, low dose atropine, or scopolamine administration reduce mortality rates, increase VF threshold, and decrease spontaneous, exercise induced, or ischemia induced ventricular fibrillation in animal models. 15,24,26,40,[65][66][67]69,[82][83][84][108][109][110] In human studies, β-blockade increase HRV in both healthy persons and patients who have had myocardial infarction, [82][83][84] as does scopolamine. 109 Type 1C antiarrhythmic drugs decrease HRV.…”
Section: Therapeutic Implications Of Heart Rate Variability Analysismentioning
confidence: 99%
“…15,24,26,40,[65][66][67]69,[82][83][84][108][109][110] In human studies, β-blockade increase HRV in both healthy persons and patients who have had myocardial infarction, [82][83][84] as does scopolamine. 109 Type 1C antiarrhythmic drugs decrease HRV. 86,87 Scopolamine in animal models and β-blockers in both animal models and humans improve survival after myocardial infarction, whereas 1C antiarrhythmic drugs increase mortality rates; however, how these effects are related to HRV is not established.…”
Section: Therapeutic Implications Of Heart Rate Variability Analysismentioning
confidence: 99%
“…It is known that beta-receptor antagonists, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers aff ect HRV and are not administered without previous testing [22][23][24][25][26] . Th e antiarrhythmics propafenone and fl ecainide reduce HRV 27 .…”
Section: Discussionmentioning
confidence: 99%